A process for preparing aminothiol ester compounds and salts thereof. The present invention relates to a process for preparing compounds of formula (I), (I) comprising the following steps: a) reacting a compound of formula (II) with an inorganic acid or an organic acid, (II) b) reacting the compound obtained in step a) with a base; c) reacting the compound obtained in step b) with CO.sub.2; d) reacting the compound obtained in step c) with an alkyl chloroformate, a reagent capable of forming, with the compound obtained in step c), an acid halide, or a reagent capable of forming, with the compound obtained in step c), a mixed anhydride; e) reacting the compound obtained in step d) with an SMe anion precursor compound.

##STR00001##

The invention relates to bimesogenic compounds of formula I

##STR00001##

wherein R.sup.11, R.sup.12, MG.sup.11, MG.sup.12, X.sup.11, X.sup.12 and Sp.sup.1 have the meaning given in claim 1, to the use of bimesogenic compounds of formula I in liquid crystal media and particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention.

Methods are provided for the synthesis of a compound of formula (X). R.sup.2 is selected from H, C.sub.1-C.sub.4-alkyl, C.sub.2-C.sub.4-alkenyl and C.sub.1-C.sub.4-aryl; R.sup.3 is selected from C(O)H and C(O)C.sub.1-C.sub.4-alkyl; and A is a pharmaceutically acceptable anion (e.g. a halide). Also provided are intermediate compounds formed during the synthesis. ##STR00001##

Methods are provided for the synthesis of a compound of formula (X). R.sup.2 is selected from H, C.sub.1-C.sub.4-alkyl, C.sub.2-C.sub.4-alkenyl and C.sub.1-C.sub.4-aryl; R.sup.3 is selected from C(O)H and C(O)C.sub.1-C.sub.4-alkyl; and A is a pharmaceutically acceptable anion (e.g. a halide). Also provided are intermediate compounds formed during the synthesis. ##STR00001##

Disclosed are cationic lipids which are compounds of Formula (I), (II), (III), (IV), (V), or (VI). Cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins. ##STR00001##

Disclosed are cationic lipids which are compounds of Formula (I), (II), (III), (IV), (V), or (VI). Cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins. ##STR00001##

The present invention relates to a process for the synthesis of cysteamine or a salt thereof.

The present invention relates to a process for the synthesis of cysteamine or a salt thereof.

The present invention provides a novel isolated succinate prodrug as the free compound or a salt, hydrate, solvate or complex thereof being cell permeable and aimed for increasing the ATP-production in mitochondria. The compound is useful in the medical treatment of a range of diseases, in nutritional supplements, nutricosmetics and in cosmetics.

The present invention provides a novel isolated succinate prodrug as the free compound or a salt, hydrate, solvate or complex thereof being cell permeable and aimed for increasing the ATP-production in mitochondria. The compound is useful in the medical treatment of a range of diseases, in nutritional supplements, nutricosmetics and in cosmetics.